Arizona State Retirement System Has $721,000 Holdings in Arvinas, Inc. (NASDAQ:ARVN)

Arizona State Retirement System grew its stake in Arvinas, Inc. (NASDAQ:ARVNGet Rating) by 7.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,719 shares of the company’s stock after buying an additional 788 shares during the period. Arizona State Retirement System’s holdings in Arvinas were worth $721,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its position in shares of Arvinas by 59.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,714 shares of the company’s stock worth $194,000 after purchasing an additional 1,014 shares during the last quarter. Nordea Investment Management AB acquired a new position in shares of Arvinas during the 1st quarter worth about $245,000. Versor Investments LP acquired a new position in shares of Arvinas during the 4th quarter worth about $345,000. Profund Advisors LLC lifted its position in shares of Arvinas by 7.0% during the 4th quarter. Profund Advisors LLC now owns 4,303 shares of the company’s stock worth $353,000 after purchasing an additional 282 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new position in shares of Arvinas during the 4th quarter worth about $381,000. Institutional investors and hedge funds own 84.52% of the company’s stock.

Analyst Ratings Changes

ARVN has been the subject of several research analyst reports. Wedbush cut Arvinas from an “outperform” rating to a “neutral” rating and set a $43.00 price objective for the company. in a research report on Monday, May 9th. Morgan Stanley initiated coverage on Arvinas in a report on Wednesday, April 6th. They issued an “equal weight” rating and a $65.00 price target for the company. The Goldman Sachs Group cut their price target on Arvinas from $111.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, May 24th. Stifel Nicolaus cut their price target on Arvinas from $93.00 to $85.00 in a report on Tuesday, April 26th. Finally, Citigroup cut their price target on Arvinas to $103.00 and set a “buy” rating for the company in a report on Friday, May 20th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Arvinas currently has an average rating of “Moderate Buy” and a consensus price target of $86.38.

Arvinas Price Performance

NASDAQ ARVN opened at $53.41 on Thursday. The firm has a market cap of $2.84 billion, a PE ratio of -12.81 and a beta of 2.00. Arvinas, Inc. has a one year low of $34.90 and a one year high of $103.53. The stock’s 50 day simple moving average is $45.67 and its 200 day simple moving average is $56.83.

Arvinas (NASDAQ:ARVNGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.35). The business had revenue of $24.20 million for the quarter, compared to the consensus estimate of $25.51 million. Arvinas had a negative return on equity of 29.38% and a negative net margin of 326.72%. The business’s revenue was up 340.0% on a year-over-year basis. As a group, equities analysts expect that Arvinas, Inc. will post -4.36 earnings per share for the current year.

Arvinas Company Profile

(Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

Featured Stories

Want to see what other hedge funds are holding ARVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arvinas, Inc. (NASDAQ:ARVNGet Rating).

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Want More Great Investing Ideas?

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.